High-altitude illnesses: Old stories and new insights into the pathophysiology, treatment and prevention

Abstract

Areas at high-altitude, annually attract millions of tourists, skiers, trekkers, and climbers. If not adequately prepared and not considering certain ascent rules, a considerable proportion of those people will suffer from acute mountain sickness (AMS) or even from life-threatening high-altitude cerebral (HACE) or/and pulmonary edema (HAPE). Reduced inspired oxygen partial pressure with gain in altitude and consequently reduced oxygen availability is primarily responsible for getting sick in this setting. Appropriate acclimatization by slowly raising the hypoxic stimulus (e.g., slow ascent to high altitude) and/or repeated exposures to altitude or artificial, normobaric hypoxia will largely prevent those illnesses. Understanding physiological mechanisms of acclimatization and pathophysiological mechanisms of high-altitude diseases, knowledge of symptoms and signs, treatment and prevention strategies will largely contribute to the risk reduction and increased safety, success and enjoyment at high altitude. Thus, this review is intended to provide a sound basis for both physicians counseling high-altitude visitors and high-altitude visitors themselves.

Keywords

Altitude / Hypoxia / Trekking / Climbing / Disease / Acute mountain sickness / Cerebral and pulmonary edema / Prevention / Therapy

References

[[1]] H. Brugger, B. Basnyat, J. Ellerton, U. Hefti, G. Strapazzon, K. Zafren. Letter to the editor: COVID-19 lung injury is different from high altitude pulmonary edema. High Alt. Med. Biol., 21 (2) ( 2020), pp. 204-205, DOI: 10.1089/ham.2020.0061

[[2]] J.J. Grannemann, A. Röper. Aufenthalte in großen Höhen nach COVID-19-Infektion - neue Aspekte der höhenmedizinischen Beratung [Travelling to High Altitude Destinations after Recovery from COVID-19-infection: new Aspects of Medical Advice in Altitude Medicine]. Pneumologie, 75 (3) ( 2021), pp. 214-220, DOI: 10.1055/a-1239-0334

[[3]] G.P. Millet, T. Debevec, F. Brocherie, M. Burtscher, J. Burtscher. Altitude and COVID-19: friend or foe? A narrative review. Physiol Rep, 8 (24) ( 2021), Article e14615, DOI: 10.14814/phy2.14615

[[4]] Government of Nepal. Nepal tourism facts.

[[5]] The most popular trekking routes on Kilimanjaro - the latest figures | CMK. Climb Mount Kilimanjaro.

[[6]] M. Burtscher, A. Ponchia. The risk of cardiovascular events during leisure time activities at altitude. Prog. Cardiovasc. Dis., 52 (6) ( 2010), pp. 507-511, DOI: 10.1016/j.pcad.2010.02.008

[[7]] M. Niedermeier, H. Gatterer, E. Pocecco, et al.. Mortality in different mountain sports activities primarily practiced in the winter season-A narrative review. Int. J. Environ. Res. Publ. Health, 17 (1) ( 2019), p. 259, DOI: 10.3390/ijerph17010259. Published 2019 Dec 30

[[8]] P.H. Hackett, R.C. Roach. High-altitude illness. N. Engl. J. Med., 345 (2) ( 2001), pp. 107-114, DOI: 10.1056/NEJM200107123450206

[[9]] K. Mairer, M. Wille, T. Bucher, M. Burtscher.Prevalence of acute mountain sickness in the Eastern Alps. High Alt. Med. Biol., 10 (3) ( 2009), pp. 239-245, DOI: 10.1089/ham.2008.1091

[[10]] N. Netzer, K. Strohl, M. Faulhaber, H. Gatterer, M. Burtscher. Hypoxia-related altitude illnesses. J. Trav. Med., 20 (4) ( 2013), pp. 247-255, DOI: 10.1111/jtm.12017

[[11]] P.H. Hackett, R.C. Roach.High altitude cerebral edema. High Alt. Med. Biol., 5 (2) ( 2004), pp. 136-146, DOI: 10.1089/1527029041352054

[[12]] P. Bärtsch, M. Maggiorini, M. Ritter, C. Noti, P. Vock, O. Oelz. Prevention of high-altitude pulmonary edema by nifedipine. N. Engl. J. Med., 325 (18) ( 1991), pp. 1284-1289, DOI: 10.1056/NEJM199110313251805

[[13]] C. Lenfant, K. Sullivan. Adaptation to high altitude. N. Engl. J. Med., 284 (23) ( 1971), pp. 1298-1309, DOI: 10.1056/NEJM197106102842305

[[14]] J.B. West, J.P. Richalet.Denis Jourdanet (1815-1892) and the early recognition of the role of hypoxia at high altitude. Am. J. Physiol. Lung Cell Mol. Physiol., 305 (5) ( 2013), pp. L333-L340, DOI: 10.1152/ajplung.00128.2013

[[15]] S.R. Muza, B.A. Beidleman, C.S. Fulco.Altitude preexposure recommendations for inducing acclimatization. High Alt. Med. Biol., 11 (2) ( 2010), pp. 87-92, DOI: 10.1089/ham.2010.1006

[[16]] C.S. Fulco, B.A. Beidleman, S.R. Muza. Effectiveness of preacclimatization strategies for high-altitude exposure. Exerc. Sport Sci. Rev., 41 (1) ( 2013), pp. 55-63, DOI: 10.1097/JES.0b013e31825eaa33

[[17]] B.A. Beidleman, C.S. Fulco, S.R. Muza, et al.. Effect of six days of staging on physiologic adjustments and acute mountain sickness during ascent to 4300 meters. High Alt. Med. Biol., 10 (3) ( 2009), pp. 253-260, DOI: 10.1089/ham.2009.1004

[[18]] K. Mairer, M. Wille, M. Burtscher.The prevalence of and risk factors for acute mountain sickness in the Eastern and Western Alps. High Alt. Med. Biol., 11 (4) ( 2010), pp. 343-348, DOI: 10.1089/ham.2010.1039

[[19]] K.E. Bloch, A.J. Turk, M. Maggiorini, et al.. Effect of ascent protocol on acute mountain sickness and success at Muztagh Ata, 7546 m. High Alt. Med. Biol., 10 (1) ( 2009), pp. 25-32, DOI: 10.1089/ham.2008.1043

[[20]] J.B. West. Human responses to extreme altitudes. Integr. Comp. Biol., 46 (1) ( 2006), pp. 25-34, DOI: 10.1093/icb/icj005

[[21]] J.B. West. Acclimatization and tolerance to extreme altitude. J. Wilderness Med., 4 (1) ( 1993), pp. 17-26, DOI: 10.1580/0953-9859-4.1.17

[[22]] A.M. Luks. Clinician's corner: what do we know about safe ascent rates at high altitude?. High Alt. Med. Biol., 13 (3) ( 2012), pp. 147-152, DOI: 10.1089/ham.2012.1055

[[23]] M. Burtscher, M. Wille, V. Menz, M. Faulhaber, H. Gatterer.Symptom progression in acute mountain sickness during a 12-hour exposure to normobaric hypoxia equivalent to 4500 m. High Alt. Med. Biol., 15 (4) ( 2014), pp. 446-451, DOI: 10.1089/ham.2014.1039

[[24]] M. Maggiorini, B. Bühler, M. Walter, O. Oelz. Prevalence of acute mountain sickness in the Swiss Alps. BMJ, 301 (6756) ( 1990), pp. 853-855, DOI: 10.1136/bmj.301.6756.853

[[25]] J.P. Richalet, P. Larmignat, E. Poitrine, M. Letournel, F. Canouï-Poitrine. Physiological risk factors for severe high-altitude illness: a prospective cohort study. Am. J. Respir. Crit. Care Med., 185 (2) ( 2012), pp. 192-198, DOI: 10.1164/rccm.201108-1396OC

[[26]] Y.P. Hou, J.L. Wu, C. Tan, Y. Chen, R. Guo, Y.J. Luo.Sex-based differences in the prevalence of acute mountain sickness: a meta-analysis. Mil Med Res, 6 (1) ( 2019), p. 38, DOI: 10.1186/s40779-019-0228-3. Published 2019 Dec 9

[[27]] V. Gianfredi, L. Albano, B. Basnyat, P. Ferrara. Does age have an impact on acute mountain sickness? A systematic review. J. Trav. Med., 27 (6) ( 2020), DOI: 10.1093/jtm/taz104. taz104

[[28]] N. Villca, A. Asturizaga, A. Heath-Freudenthal. High-altitude illnesses and air travel: pediatric considerations. Pediatr Clin North Am, 68 (1) ( 2021), pp. 305-319, DOI: 10.1016/j.pcl.2020.09.015

[[29]] R.C. Roach, P. Bärtsch, P.H. Hackett, O. Oelz. The Lake Louise acute mountain sickness scoring system. J.R.H.C. Sutton, G. Coates (Eds.), Hypoxia and Molecular Medicine, Queen City Press ( 1993), pp. 272-274. (Conference preceding)

[[30]] R.C. Roach, P.H. Hackett, O. Oelz, et al.. The 2018 lake louise acute mountain sickness score. High Alt. Med. Biol., 19 (1) ( 2018), pp. 4-6, DOI: 10.1089/ham.2017.0164

[[31]] D.R. Wagner, M. Teramoto, J.R. Knott, J.P. Fry.Comparison of scoring systems for assessment of acute mountain sickness. High Alt. Med. Biol., 13 (4) ( 2012), pp. 245-251, DOI: 10.1089/ham.2012.1030

[[32]] G.P. Millet, T. Debevec. CrossTalk proposal: barometric pressure, independent of PO2, is the forgotten parameter in altitude physiology and mountain medicine. J Physiol, 598 (5) ( 2020), pp. 893-896, DOI: 10.1113/JP278673

[[33]] J.P. Richalet. CrossTalk opposing view: barometric pressure, independent of PO2, is not the forgotten parameter in altitude physiology and mountain medicine. J Physiol, 598 (5) ( 2020), pp. 897-899, DOI: 10.1113/JP279160

[[34]] M. Pun. The physiologic basis of high-altitude diseases. Ann. Intern. Med., 142 (7) ( 2005), pp. 591-592, DOI: 10.7326/0003-4819-142-7-200504050-00023

[[35]] G.L. Semenza. Hypoxia-inducible factors in physiology and medicine. Cell, 148 (3) ( 2012), pp. 399-408, DOI: 10.1016/j.cell.2012.01.021

[[36]] V.H. Haase. Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev., 27 (1) ( 2013), pp. 41-53, DOI: 10.1016/j.blre.2012.12.003

[[37]] A. Weidemann, R.S. Johnson. Biology of HIF-1 alpha. Cell Death Differ., 15 (4) ( 2008), pp. 621-627, DOI: 10.1038/cdd.2008.12

[[38]] C.T. Taylor. Mitochondria and cellular oxygen sensing in the HIF pathway. Biochem. J., 409 (1) ( 2008), pp. 19-26, DOI: 10.1042/BJ20071249

[[39]] J.V. Weil, E. Byrne-Quinn, I.E. Sodal, et al.. Hypoxic ventilatory drive in normal man. J. Clin. Invest., 49 (6) ( 1970), pp. 1061-1072, DOI: 10.1172/JCI106322

[[40]] J.T. Reeves. Sympathetics and hypoxia:a brief overview. In: Hypoxiaand Molecular Medicine, editedby, SuttonJ.R., HoustonC., CoatesG. BurlingtonVT. Queen City ( 1993), pp. 1-6

[[41]] P. Bärtsch, J.S. Gibbs. Effect of altitude on the heart and the lungs. Circulation, 116 (19) ( 2007), pp. 2191-2202, DOI: 10.1161/CIRCULATIONAHA.106.650796

[[42]] P.R. Bender, R.E. McCullough, R.G. McCullough, et al.. Increased exercise SaO 2 independent of ventilatory acclimatization at 4,300 m. ( 1985). J. Appl. Physiol., 66 (6) ( 1989), pp. 2733-2738, DOI: 10.1152/jappl.1989.66.6.2733

[[43]] M. Sato, J.W. Severinghaus, P. Bickler.Time course of augmentation and depression of hypoxic ventilatory responses at altitude. ( 1985). J. Appl. Physiol., 77 (1) ( 1994), pp. 313-316, DOI: 10.1152/jappl.1994.77.1.313

[[44]] S.M. Zouboules, H.C. Lafave, K.D. O'Halloran, et al.. Renal reactivity: acid-base compensation during incremental ascent to high altitude. J Physiol, 596 (24) ( 2018), pp. 6191-6203, DOI: 10.1113/JP276973

[[45]] P.N. Ainslie, A.W. Subudhi.Cerebral blood flow at high altitude. High Alt. Med. Biol., 15 (2) ( 2014), pp. 133-140, DOI: 10.1089/ham.2013.1138

[[46]] D.M. Bailey, S. Taudorf, R.M. Berg, et al.. Increased cerebral output of free radicals during hypoxia: implications for acute mountain sickness?. Am. J. Physiol. Regul. Integr. Comp. Physiol., 297 (5) ( 2009), pp. R1283-R1292, DOI: 10.1152/ajpregu.00366.2009

[[47]] G. Strapazzon, S. Malacrida, A. Vezzoli, et al.. Oxidative stress response to acute hypobaric hypoxia and its association with indirect measurement of increased intracranial pressure: a field study. Sci. Rep., 6 ( 2016), p. 32426, DOI: 10.1038/srep32426. Published 2016 Aug 31

[[48]] J.P. Richalet, A. Hornych, C. Rathat, J. Aumont, P. Larmignat, P. Rémy. Plasma prostaglandins, leukotrienes and thromboxane in acute high altitude hypoxia. Respir. Physiol., 85 (2) ( 1991), pp. 205-215, DOI: 10.1016/0034-5687(91)90062-n

[[49]] H.K. Eltzschig, P. Carmeliet. Hypoxia and inflammation. N. Engl. J. Med., 364 (7) ( 2011), pp. 656-665, DOI: 10.1056/NEJMra0910283

[[50]] S.A. McGuire, P.M. Sherman, S.A. Wijtenburg, et al.. White matter hyperintensities and hypobaric exposure. Ann. Neurol., 76 (5) ( 2014), pp. 719-726. https://doi:10.1002/ana.24264

[[51]] R.C. Roach, J.A. Loeppky, M.V. Icenogle. Acute mountain sickness: increased severity during simulated altitude compared with normobaric hypoxia. J. Appl. Physiol., 81 (5) ( 1996), pp. 1908-1910, DOI: 10.1152/jappl.1996.81.5.1908. (1985)

[[52]] D.M. DiPasquale, G.E. Strangman, N.S. Harris, S.R. Muza. Acute mountain sickness symptoms depend on normobaric versus hypobaric hypoxia. BioMed Res. Int., 2016 ( 2016), p. 6245609, DOI: 10.1155/2016/6245609

[[53]] D.J. Dubowitz, E.A. Dyer, R.J. Theilmann, R.B. Buxton,S.R. Hopkins. Early brain swelling in acute hypoxia

1985). J. Appl. Physiol., 107 (1) ( 2009), pp. 244-252, DOI: 10.1152/japplphysiol.90349.2008

[[54]] K. Kallenberg, D.M. Bailey, S. Christ, et al.. Magnetic resonance imaging evidence of cytotoxic cerebral edema in acute mountain sickness. J. Cerebr. Blood Flow Metabol., 27 (5) ( 2007), pp. 1064-1071, DOI: 10.1038/sj.jcbfm.9600404

[[55]] G.G. Schoonman, P.S. Sándor, A.C. Nirkko, et al.. Hypoxia-induced acute mountain sickness is associated with intracellular cerebral edema: a 3 T magnetic resonance imaging study. J. Cerebr. Blood Flow Metabol., 28 (1) ( 2008), pp. 198-206, DOI: 10.1038/sj.jcbfm.9600513

[[56]] R.S. Sagoo, C.E. Hutchinson, A. Wright, et al.. Magnetic Resonance investigation into the mechanisms involved in the development of high-altitude cerebral edema. J. Cerebr. Blood Flow Metabol., 37 (1) ( 2017), pp. 319-331, DOI: 10.1177/0271678X15625350

[[57]] M. Sanchez del Rio, M.A. Moskowitz. High altitude headache. Lessons from headaches at sea level. Adv. Exp. Med. Biol., 474 ( 1999), pp. 145-153

[[58]] M. Serrano-Dueñas. High-altitude headache. Expert Rev. Neurother., 7 (3) ( 2007), pp. 245-248, DOI: 10.1586/14737175.7.3.245

[[59]] M. Burtscher, R. Likar, W. Nachbauer, M. Philadelphy. Aspirin for prophylaxis against headache at high altitudes: randomised, double blind, placebo controlled trial. BMJ, 316 (7137) ( 1998), pp. 1057-1058, DOI: 10.1136/bmj.316.7137.1057

[[60]] A.M. Luks, E.R. Swenson,P. Bärtsch. Acute high-altitude sickness. Eur. Respir. Rev., 26 (143) ( 2017), p. 160096, DOI: 10.1183/16000617.0096-2016. Published 2017 Jan 31

[[61]] L. Kudrow. The pathogenesis of cluster headache. Curr. Opin. Neurol., 7 (3) ( 1994), pp. 278-282, DOI: 10.1097/00019052-199406000-00017

[[62]] R.C. Roach, D. Maes, D. Sandoval, et al.. Exercise exacerbates acute mountain sickness at simulated high altitude. ( 1985). J. Appl. Physiol., 88 (2) ( 2000), pp. 581-585, DOI: 10.1152/jappl.2000.88.2.581

[[63]] J.W. Castellani, S.R. Muza, S.N. Cheuvront, et al.. Effect of hypohydration and altitude exposure on aerobic exercise performance and acute mountain sickness. ( 1985). J. Appl. Physiol., 109 (6) ( 2010), pp. 1792-1800, DOI: 10.1152/japplphysiol.00517.2010

[[64]] M. Burtscher, K. Mairer, M. Wille, G. Broessner. Risk factors for high-altitude headache in mountaineers. Cephalalgia, 31 (6) ( 2011), pp. 706-711, DOI: 10.1177/0333102410394678

[[65]] C.G. Julian, A.W. Subudhi, M.J. Wilson, A.C. Dimmen, T. Pecha, R.C. Roach.Acute mountain sickness, inflammation, and permeability: new insights from a blood biomarker study. ( 1985). J. Appl. Physiol., 111 (2) ( 2011), pp. 392-399, DOI: 10.1152/japplphysiol.00391.2011

[[66]] P. Bärtsch, E.R. Swenson. Clinical practice: acute high-altitude illnesses. N. Engl. J. Med., 368 (24) ( 2013), pp. 2294-2302, DOI: 10.1056/NEJMcp1214870

[[67]] D. Simancas-Racines, I. Arevalo-Rodriguez, D. Osorio, J.V. Franco, Y. Xu, R. Hidalgo. Interventions for treating acute high altitude illness. Cochrane Database Syst. Rev., 6 (6) ( 2018), DOI: 10.1002/14651858.CD009567.pub2. CD009567. Published 2018 Jun 30

[[68]] H.R. Irons, R.N. Salas, S.F. Bhai, W.D. Gregorie, N.S. Harris.Prospective double-blinded randomized field-based clinical trial of metoclopramide and ibuprofen for the treatment of high altitude headache and acute mountain sickness. Wilderness Environ. Med., 31 (1) ( 2020), pp. 38-43, DOI: 10.1016/j.wem.2019.11.005

[[69]] P.H. Hackett, D. Rennie, H.D. Levine. The incidence, importance, and prophylaxis of acute mountain sickness. Lancet, 2 (7996) ( 1976), pp. 1149-1155, DOI: 10.1016/s0140-6736(76)91677-9

[[70]] T.Y. Wu, S.Q. Ding, J.L. Liu, et al.. Who should not go high: chronic disease and work at altitude during construction of the Qinghai-Tibet railroad. High Alt. Med. Biol., 8 (2) ( 2007), pp. 88-107, DOI: 10.1089/ham.2007.1015

[[71]] T. Wu, S. Ding, J. Liu, et al.. Ataxia: an early indicator in high altitude cerebral edema. High Alt. Med. Biol., 7 (4) ( 2006), pp. 275-280, DOI: 10.1089/ham.2006.7.275

[[72]] C. Davis, P. Hackett. Advances in the prevention and treatment of high altitude illness. Emerg Med Clin North Am, 35 (2) ( 2017), pp. 241-260, DOI: 10.1016/j.emc.2017.01.002

[[73]] P.H. Hackett, P.R. Yarnell, R. Hill, K. Reynard, J. Heit, J. McCormick. High-altitude cerebral edema evaluated with magnetic resonance imaging: clinical correlation and pathophysiology. J. Am. Med. Assoc., 280 (22) ( 1998), pp. 1920-1925, DOI: 10.1001/jama.280.22.1920

[[74]] J.V. Lafuente, G. Bermudez, L. Camargo-Arce, S. Bulnes. Blood-Brain barrier changes in high altitude. CNS Neurol. Disord. - Drug Targets, 15 (9) ( 2016), pp. 1188-1197, DOI: 10.2174/1871527315666160920123911

[[75]] M. Simka, P. Latacz, J. Czaja.Possible role of glymphatic system of the brain in the pathogenesis of high-altitude cerebral edema. High Alt. Med. Biol., 19 (4) ( 2018), pp. 394-397, DOI: 10.1089/ham.2018.0066

[[76]] K. Schommer, K. Kallenberg, K. Lutz, P. Bärtsch, M. Knauth. Hemosiderin deposition in the brain as footprint of high-altitude cerebral edema. Neurology, 81 (20) ( 2013), pp. 1776-1779, DOI: 10.1212/01.wnl.0000435563.84986.78

[[77]] J. Pichler Hefti, P. Hoigné-Perret, R. Kottke.Extensive microhemorrhages of the cerebellar peduncles after high-altitude cerebral edema. High Alt. Med. Biol., 18 (2) ( 2017), pp. 182-184, DOI: 10.1089/ham.2016.0103

[[78]] R. Kottke, J. Pichler Hefti, C. Rummel, M. Hauf, U. Hefti, T.M. Merz. Morphological brain changes after climbing to extreme altitudes--A prospective cohort study. PloS One, 10 (10) ( 2015), Article e0141097, DOI: 10.1371/journal.pone.0141097. Published 2015 Oct 28

[[79]] R.B. Schoene. Illnesses at high altitude. Chest, 134 (2) ( 2008), pp. 402-416, DOI: 10.1378/chest.07-0561

[[80]] A.L. Gabry, X. Ledoux, M. Mozziconacci, C. Martin. High-altitude pulmonary edema at moderate altitude (< 2,400 m; 7,870 feet): a series of 52 patients. Chest, 123 (1) ( 2003), pp. 49-53, DOI: 10.1378/chest.123.1.49

[[81]] A.M. Sophocles Jr., J. Bachman. High-altitude pulmonary edema among visitors to Summit County, Colorado. J. Fam. Pract., 17 (6) ( 1983), pp. 1015-1017

[[82]] P. Bärtsch, M. Maggiorini, H. Mairbäurl, P. Vock, E.R. Swenson. Pulmonary extravascular fluid accumulation in climbers. Lancet, 360 (9332) ( 2002), pp. 571-572, DOI: 10.1016/S0140-6736(02)09723-4

[[83]] R.B. Schoene. Pulmonary edema at high altitude. Review, pathophysiology, and update. Clin. Chest Med., 6 (3) ( 1985), pp. 491-507

[[84]] E.R. Swenson, P. Bärtsch. High-altitude pulmonary edema. Comp. Physiol., 2 (4) ( 2012), pp. 2753-2773, DOI: 10.1002/cphy.c100029

[[85]] O. Oelz, M. Maggiorini, M. Ritter, et al.. Prevention and treatment of high altitude pulmonary edema by a calcium channel blocker. Int. J. Sports Med., 13 (Suppl 1) ( 1992), pp. S65-S68, DOI: 10.1055/s-2007-1024598

[[86]] E.R. Swenson, M. Maggiorini, S. Mongovin, et al.. Pathogenesis of high-altitude pulmonary edema: inflammation is not an etiologic factor. [published correction appears in JAMA 2002 Sep 4;288

( 9:1064. J. Am. Med. Assoc., 287 (17) (2002 ) , pp. 2228-2235, DOI: 10.1001/jama.287.17.2228

[[87]] C. Dehnert, D. Mereles, S. Greiner, et al.. Exaggerated hypoxic pulmonary vasoconstriction without susceptibility to high altitude pulmonary edema. High Alt. Med. Biol., 16 (1) ( 2015), pp. 11-17, DOI: 10.1089/ham.2014.1117

[[88]] C.A. Eichstaedt, H. Mairbäurl, J. Song, et al.. Genetic predisposition to high-altitude pulmonary edema. High Alt. Med. Biol., 21 (1) ( 2020), pp. 28-36, DOI: 10.1089/ham.2019.0083

[[89]] U. Scherrer, P. Turini, S. Thalmann, et al.. Pulmonary hypertension in high-altitude dwellers: novel mechanisms, unsuspected predisposing factors. Adv. Exp. Med. Biol., 588 ( 2006), pp. 277-291, DOI: 10.1007/978-0-387-34817-9_23

[[90]] C. Sartori, H. Duplain, M. Lepori, et al.. High altitude impairs nasal transepithelial sodium transport in HAPE-prone subjects. Eur. Respir. J., 23 (6) ( 2004), pp. 916-920, DOI: 10.1183/09031936.04.00115304

[[91]] Y. Allemann, D. Hutter, E. Lipp, et al.. Patent foramen ovale and high-altitude pulmonary edema. J. Am. Med. Assoc., 296 (24) ( 2006), pp. 2954-2958, DOI: 10.1001/jama.296.24.2954

[[92]] B.E. Marshall, C. Marshall, M. Magno, P. Lilagan, G.G. Pietra.Influence of bronchial arterial PO2 on pulmonary vascular resistance. ( 1985). J. Appl. Physiol., 70 (1) ( 1991), pp. 405-415, DOI: 10.1152/jappl.1991.70.1.405

[[93]] E.R. Swenson. Hypoxic pulmonary vasoconstriction. High Alt. Med. Biol., 14 (2) ( 2013), pp. 101-110, DOI: 10.1089/ham.2013.1010

[[94]] R.B. Schoene, R.C. Roach, P.H. Hackett, G. Harrison, W.J. Mills Jr.. High altitude pulmonary edema and exercise at 4,400 meters on Mount McKinley. Effect of expiratory positive airway pressure. Chest, 87 (3) ( 1985), pp. 330-333, DOI: 10.1378/chest.87.3.330

[[95]] E.R. Swenson.Early hours in the development of high-altitude pulmonary edema: time course and mechanisms. ( 1985). J. Appl. Physiol., 128 (6) ( 2020), pp. 1539-1546, DOI: 10.1152/japplphysiol.00824.2019

[[96]] J.B. West.Climbing Mt. Everest without oxygen: an analysis of maximal exercise during extreme hypoxia. Respir. Physiol., 52 (3) ( 1983), pp. 265-279, DOI: 10.1016/0034-5687(83)90085-3

[[97]] M. Burtscher, H. Gatterer, A. Kleinsasser.Cardiorespiratory fitness of high altitude mountaineers: the underestimated prerequisite. High Alt. Med. Biol., 16 (2) ( 2015), pp. 169-170, DOI: 10.1089/ham.2015.0021

[[98]] G.M.K. Rossetti, J.H. Macdonald, M. Smith, et al.. MEDEX2015: greater sea-level fitness is associated with lower sense of effort during Himalayan trekking without worse acute mountain sickness. High Alt. Med. Biol., 18 (2) ( 2017), pp. 152-162, DOI: 10.1089/ham.2016.0088

[[99]] A.E. Minetti, F. Formenti, L.P. Ardigò. Himalayan porter's specialization: metabolic power, economy, efficiency and skill. Proc. Biol. Sci., 273 (1602) ( 2006), pp. 2791-2797, DOI: 10.1098/rspb.2006.3653

[[100]] S. Mohajeri, B.A. Perkins, P.L. Brubaker, M.C. Riddell. Diabetes, trekking and high altitude: recognizing and preparing for the risks. Diabet. Med., 32 (11) ( 2015), pp. 1425-1437, DOI: 10.1111/dme.12795

[[101]] G. Parati, P. Agostoni, B. Basnyat, et al.. Clinical recommendations for high altitude exposure of individuals with pre-existing cardiovascular conditions: a joint statement by the European Society of Cardiology, the Council on hypertension of the European Society of Cardiology, the European Society of hypertension, the international Society of mountain medicine, the Italian Society of hypertension and the Italian Society of mountain medicine. Eur. Heart J., 39 (17) ( 2018), pp. 1546-1554, DOI: 10.1093/eurheartj/ehx720

[[102]] P. Bärtsch, E. Grünig, E. Hohenhaus, C. Dehnert.Assessment of high altitude tolerance in healthy individuals. High Alt. Med. Biol., 2 (2) ( 2001), pp. 287-296, DOI: 10.1089/152702901750265378

[[103]] B. Basnyat, D.R. Murdoch. High-altitude illness. Lancet, 361 (9373) ( 2003), pp. 1967-1974, DOI: 10.1016/S0140-6736(03)13591-X

[[104]] A.M. Luks.Physiology in Medicine: a physiologic approach to prevention and treatment of acute high-altitude illnesses

1985). J. Appl. Physiol., 118 (5) ( 2015), pp. 509-519, DOI: 10.1152/japplphysiol.00955.2014

[[105]] J.B. West. Highest inhabitants in the world. Nature, 324 (6097) ( 1986), p. 517, DOI: 10.1038/324517a0

[[106]] L.G. Pugh.Man at high altitude: studies carried out in the Himalaya. Sci. Basis Med. Annu. Rev. ( 1964), pp. 32-54

[[107]] M. Ward. High altitude deterioration. Proc. R. Soc. Lond. B Biol. Sci., 143 (910) ( 1954), pp. 40-42, DOI: 10.1098/rspb.1954.0052

[[108]] P. Cerretelli. Muscle energetics and ultrastructure in chronic hypoxia. Respiration, 59 (Suppl 2) ( 1992), pp. 24-29, DOI: 10.1159/000196117

[[109]] J.P. Richalet, F. Pillard, D. Le Moal, et al.. Validation of a score for the detection of subjects with high risk for severe high-altitude illness

[published online ahead of print, 2020 Dec 29].Med. Sci. Sports Exerc. ( 2020), DOI: 10.1249/MSS.0000000000002586. Publish Ahead of Print:10.1249/MSS.0000000000002586

[[110]] C.S. Fulco, S.R. Muza, B. Beidleman, et al.. Exercise performance of sea-level residents at 4300 m after 6 days at 2200 m. Aviat Space Environ. Med., 80 (11) ( 2009), pp. 955-961, DOI: 10.3357/asem.2540.2009

[[111]] H. Benoit, M. Germain, J.C. Barthélémy, et al.. Pre-acclimatization to high altitude using exercise with normobaric hypoxic gas mixtures. Int. J. Sports Med., 13 (Suppl 1) ( 1992), pp. S213-S216, DOI: 10.1055/s-2007-1024643

[[112]] A. Ponchia, D. Noventa, M. Bertaglia, et al.. Cardiovascular neural regulation during and after prolonged high altitude exposure. Eur. Heart J., 15 (11) ( 1994), pp. 1463-1469, DOI: 10.1093/oxfordjournals.eurheartj.a060415

[[113]] G. Savourey, N. Garcia, Y. Besnard, A.M. Hanniquet, M.O. Fine, J. Bittel. Physiological changes induced by pre-adaptation to high altitude. Eur. J. Appl. Physiol. Occup. Physiol., 69 (3) ( 1994), pp. 221-227, DOI: 10.1007/BF01094792

[[114]] J.E. Staab, B.A. Beidleman, S.R. Muza, C.S. Fulco, P.B. Rock, A. Cymerman.Efficacy of residence at moderate versus low altitude on reducing acute mountain sickness in men following rapid ascent to 4300 m. High Alt. Med. Biol., 14 (1) ( 2013), pp. 13-18, DOI: 10.1089/ham.2012.1065

[[115]] M. Schneider, D. Bernasch, J. Weymann, R. Holle, P. Bartsch.Acute mountain sickness: influence of susceptibility, preexposure, and ascent rate. Med. Sci. Sports Exerc., 34 (12) ( 2002), pp. 1886-1891, DOI: 10.1097/00005768-200212000-00005

[[116]] M.P. Hilty, U. Hefti, H. Brugger, P. Bouzat.Letter to the Editor: preacclimatization for Expeditions to Extreme Altitude: an Opinion Position from the Union Internationale des Associations d'Alpinisme Medical Commission. High Alt. Med. Biol., 21 (3) ( 2020), pp. 303-304, DOI: 10.1089/ham.2020.0029

[[117]] R.L. Burse, V.A. Forte Jr.. Acute mountain sickness at4500 m is not altered by repeated eight-hour exposures to 3200-3550 m normobaric hypoxic equivalent. Aviat Space Environ. Med., 59 (10) ( 1988), pp. 942-949

[[118]] A. Ricart, H. Casas, M. Casas, et al.. Acclimatization near home? Early respiratory changes after short-term intermittent exposure to simulated altitude. Wilderness Environ. Med., 11 (2) ( 2000), pp. 84-88, DOI: 10.1580/1080-6032(2000)011[0084:anherc]2.3.co;2

[[119]] M. Casas, H. Casas, T. Pagés, et al.. Intermittent hypobaric hypoxia induces altitude acclimation and improves the lactate threshold. Aviat Space Environ. Med., 71 (2) ( 2000), pp. 125-130

[[120]] C.S. Fulco, S.R. Muza, B.A. Beidleman, et al.. Effect of repeated normobaric hypoxia exposures during sleep on acute mountain sickness, exercise performance, and sleep during exposure to terrestrial altitude. Am. J. Physiol. Regul. Integr. Comp. Physiol., 300 (2) ( 2011), pp. R428-R436, DOI: 10.1152/ajpregu.00633.2010

[[121]] M. Wille, H. Gatterer, K. Mairer, et al.. Short-term intermittent hypoxia reduces the severity of acute mountain sickness. Scand. J. Med. Sci. Sports, 22 (5) ( 2012), pp. e79-e85, DOI: 10.1111/j.1600-0838.2012.01499.x

[[122]] M. Faulhaber, E. Pocecco, H. Gatterer, et al.. Seven passive 1-h hypoxia exposures do not prevent AMS in susceptible individuals. Med. Sci. Sports Exerc., 48 (12) ( 2016), pp. 2563-2570, DOI: 10.1249/MSS.0000000000001036

[[123]] C. Dehnert, A. Böhm, I. Grigoriev, E. Menold, P. Bärtsch.Sleeping in moderate hypoxia at home for prevention of acute mountain sickness (AMS): a placebo-controlled, randomized double-blind study. Wilderness Environ. Med., 25 (3) ( 2014), pp. 263-271, DOI: 10.1016/j.wem.2014.04.004

[[124]] B. Treml, A. Kleinsasser, T. Hell, H. Knotzer, M. Wille, M. Burtscher. Carry-over quality of pre-acclimatization to altitude elicited by intermittent hypoxia: a participant-blinded, randomized controlled trial on antedated acclimatization to altitude. Front. Physiol., 11 ( 2020), p. 531, DOI: 10.3389/fphys.2020.00531. Published 2020 May 29

[[125]] A.J. Ellsworth, E.B. Larson, D. Strickland. A randomized trial of dexamethasone and acetazolamide for acute mountain sickness prophylaxis. Am. J. Med., 83 (6) ( 1987), pp. 1024-1030, DOI: 10.1016/0002-9343(87)90937-5

[[126]] B. Basnyat, J.H. Gertsch, E.W. Johnson, F. Castro-Marin, Y. Inoue, C. Yeh.Efficacy of low-dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double-blind, randomized, placebo-controlled trial. High Alt. Med. Biol., 4 (1) ( 2003), pp. 45-52, DOI: 10.1089/152702903321488979

[[127]] J.H. Gertsch, G.S. Lipman, P.S. Holck, et al.. Prospective, double-blind, randomized, placebo-controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT). Wilderness Environ. Med., 21 (3) ( 2010), pp. 236-243, DOI: 10.1016/j.wem.2010.06.009

[[128]] E.R. Swenson. Carbonic anhydrase inhibitors and hypoxic pulmonary vasoconstriction. Respir. Physiol. Neurobiol., 151 (2-3) ( 2006), pp. 209-216, DOI: 10.1016/j.resp.2005.10.011

[[129]] E.R. Swenson, L.J. Teppema. Prevention of acute mountain sickness by acetazolamide: as yet an unfinished story. J. Appl. Physiol., 102 (4) ( 2007), pp. 1305-1307, DOI: 10.1152/japplphysiol.01407.2006. (1985)

[[130]] E.R. Swenson. Carbonic anhydrase inhibitors and high altitude illnesses. Subcell. Biochem., 75 ( 2014), pp. 361-386, DOI: 10.1007/978-94-007-7359-2_18

[[131]] B. Kayser, L. Dumont, C. Lysakowski, C. Combescure, G. Haller, M.R. Tramèr.Reappraisal of acetazolamide for the prevention of acute mountain sickness: a systematic review and meta-analysis. High Alt. Med. Biol., 13 (2) ( 2012), pp. 82-92, DOI: 10.1089/ham.2011.1084

[[132]] B. Basnyat, J.H. Gertsch, P.S. Holck, et al.. Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial. High Alt. Med. Biol., 7 (1) ( 2006), pp. 17-27, DOI: 10.1089/ham.2006.7.17

[[133]] S.E. McIntosh, M. Hemphill, M.C. McDevitt, et al.. Reduced acetazolamide dosing in countering altitude illness: a comparison of 62.5 vs 125 mg (the RADICAL trial). Wilderness Environ. Med., 30 (1) ( 2019), pp. 12-21, DOI: 10.1016/j.wem.2018.09.002

[[134]] M. Burtscher, H. Gatterer, M. Faulhaber, J. Burtscher. Acetazolamide pre-treatment before ascending to high altitudes: when to start?. Int. J. Clin. Exp. Med., 7 (11) ( 2014), pp. 4378-4383. Published 2014 Nov 15

[[135]] G.S. Lipman, C. Jurkiewicz, C. Winstead-Derlega, et al.. Day of ascent dosing of acetazolamide for prevention of acute mountain sickness. High Alt. Med. Biol., 20 (3) ( 2019), pp. 271-278, DOI: 10.1089/ham.2019.0007

[[136]] H.M. Liu, I.J. Chiang, K.N. Kuo, C.M. Liou, C. Chen. The effect of acetazolamide on sleep apnea at high altitude: a systematic review and meta-analysis. Ther. Adv. Respir. Dis., 11 (1) ( 2017), pp. 20-29, DOI: 10.1177/1753465816677006

[[137]] H. Lu, H. Zhang, Y. Jiang.Methazolamide in high-altitude illnesses. Eur. J. Pharmaceut. Sci., 148 ( 2020), p. 105326, DOI: 10.1016/j.ejps.2020.105326

[[138]] M. Schilling, S. Irarrázaval. Ibuprofen versus acetazolamide for prevention of acute mountain sickness. Ibuprofeno comparado con acetazolamida para prevención de mal agudo de montaña. Medwave, 20 (5) ( 2020), Article e7733, DOI: 10.5867/medwave.2020.05.7732. Published 2020 Jun 11

[[139]] M. Maggiorini, H.P. Brunner-La Rocca, S. Peth, et al.. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial. Ann. Intern. Med., 145 (7) ( 2006), pp. 497-506, DOI: 10.7326/0003-4819-145-7-200610030-00007

[[140]] C. Sartori, Y. Allemann, H. Duplain, et al.. Salmeterol for the prevention of high-altitude pulmonary edema. N. Engl. J. Med., 346 (21) ( 2002), pp. 1631-1636, DOI: 10.1056/NEJMoa013183

[[141]] M.A. Matthay, H.R. Flori, E.R. Conner, L.B. Ware. Alveolar epithelial fluid transport: basic mechanisms and clinical relevance. Proc. Assoc. Am. Phys., 110 (6) ( 1998), pp. 496-505

[[142]] J.H. Gertsch, T.B. Seto, J. Mor, J. Onopa.Ginkgo biloba for the prevention of severe acute mountain sickness (AMS) starting one day before rapid ascent. High Alt. Med. Biol., 3 (1) ( 2002), pp. 29-37, DOI: 10.1089/152702902753639522

[[143]] L. Dumont, C. Mardirosoff, M.R. Tramèr. Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review. BMJ, 321 (7256) ( 2000), pp. 267-272, DOI: 10.1136/bmj.321.7256.267

[[144]] J.H. Gertsch, B. Basnyat, E.W. Johnson, J. Onopa, P.S. Holck. Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ, 328 (7443) ( 2004), p. 797, DOI: 10.1136/bmj.38043.501690.7C

[[145]] T. Chow, V. Browne, H.L. Heileson, D. Wallace, J. Anholm, S.M. Green. Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo-controlled trial. Arch. Intern. Med., 165 (3) ( 2005), pp. 296-301, DOI: 10.1001/archinte.165.3.296